Warranty Issues of PDE-5 Inhibitors as Off-Label Use Action Mechanism based on Pharmacoeconomics for Patient Safety in Taxation System

ABSTRACT

Every government system follows the principle of ultimate powers in divided authorities responsible to promote public welfare and safety through constitutional practice of economic freedom. Pharmacoeconomics deals with cost-effective analysis in alignment with administrative functions of the government in relation to ethical behavior of private companies to comply with the rules and regulations expressed by the legislation and its comparative parliamentary legal system for guidance and control of appropriate ethical conduct as advocated by warranty issues of intellectual property. The intended design of PDE-5 inhibitors for marketing their products for public use as medication is indicated in their patent registration as strict compliance of advocating patient safety. Hence, ethical issues on product warranty of declared intended use, health risks for economic benefit, sexuality, and gender as socio-legal utilization of resources, empirical healthcare practice based on registered declared intellectual property of product design, and economic interventions in advocacy of constitutional monetary freedom are aimed to be discussed and resolved in this paper. Public funds are used by the government to advocate cost-effective analysis in pharmacoeconomics. Therefore, direct taxation of product services and practice of health promotion must be properly addressed and coordination in aligning the institutional goals with employment law for proper compliance of handling patented products. Furthermore, indirect taxation based on public funds must resolve issues concerning taxes collected from private companies handling patented drug products with clear specification of intended design for patient efficacy and safety. It is recommended to provide ways of promoting pharmacoeconomics without the conflict of suffering the declared intellectual property design for handling and misleading the acquired taxes for public funds, which in turn will also be compensated for unregistered intellectual property design based on patent law.   

Keywords: pharmacoeconomics, off-label use, taxation, intellectual property, patient safety